Kazia Therapeutics EV/EBITDA
Qual é o EV/EBITDA de Kazia Therapeutics?
O EV/EBITDA de Kazia Therapeutics Limited é N/A
Qual é a definição de EV/EBITDA?
EV/EBITDA é o valor da empresa dividido pelo lucro antes de juros, impostos, depreciação e amortização. É uma medida de quão cara é uma ação e é mais frequentemente válida para comparações entre empresas do que da relação entre preço e lucro. Ele mede o preço (na forma de valor da empresa) que um investidor paga em benefício do fluxo de caixa da empresa (na forma de EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA de empresas na Setor Health Care em ASX em comparação com Kazia Therapeutics
O que Kazia Therapeutics faz?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Empresas com ev/ebitda semelhantes a Kazia Therapeutics
- NeonMind Biosciences tem EV/EBITDA de N/A
- Lumos Diagnostics tem EV/EBITDA de N/A
- Bluewater Acquisition Corp tem EV/EBITDA de N/A
- Guyana Goldstrike Inc tem EV/EBITDA de N/A
- BrewBilt Manufacturing tem EV/EBITDA de N/A
- Sable Resources tem EV/EBITDA de N/A
- Kazia Therapeutics tem EV/EBITDA de N/A
- engage:BDR tem EV/EBITDA de N/A
- Viaan Industries tem EV/EBITDA de N/A
- Antera Ventures Ii Corp tem EV/EBITDA de N/A
- MacDonald Mines Exploration tem EV/EBITDA de N/A
- Sihayo Gold tem EV/EBITDA de N/A
- Fabled Copper tem EV/EBITDA de N/A